{"groups":[{"description":"Patients receive tremelimumab and durvalumab as in Arm C. Beginning at week 2, patients receive high dose radiation therapy QD over 10 days for up to 3 fractions.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"FG000","title":"NSCLC Arm A (Tremelimumab, Durvalumab, HD-RT)"},{"description":"Patients receive tremelimumab and durvalumab as in Arm C. Beginning at week 2, patients receive low dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"FG001","title":"NSCLC Arm B (Tremelimumab, Durvalumab, LD-RT)"},{"description":"Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses.\n\nDurvalumab: Given IV\n\nTremelimumab: Given IV","id":"FG002","title":"NSCLC Arm C (Tremelimumab, Durvalumab)"},{"description":"Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses. Beginning at week 2, patients receive high dose radiation therapy QD over 10 days for up to 3 fractions.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"FG003","title":"CRC Arm A (Tremelimumab, Druvalumab, HD-RT)"},{"description":"Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses. Beginning at week 2, patients receive low dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"FG004","title":"CRC Arm B (Tremelimumab, Dervalumab, LD-RT)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"Disease progression before treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"Patient ineligible"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"30"},{"groupId":"FG002","numSubjects":"30"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"10"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"26"},{"groupId":"FG002","numSubjects":"26"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"9"}],"type":"Received Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"26"},{"groupId":"FG002","numSubjects":"26"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"9"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"NSCLC: Ninety participants were randomized (30 per arm). A total of twelve participants either withdrew consent (N=5) before starting protocol therapy, were found to be ineligible (N=4), or progressed prior to starting protocol therapy (N=3) and were not included in the analysis.\n\nCRC: Twenty patients were randomized (10 per arm). One patient (Arm B) never started protocol therapy.","recruitmentDetails":"Participants were recruited from 18 medical centers. The first participant was enrolled in August 2017 and the last in March 2019."}